|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1992-4-3
|
|
pubmed:abstractText |
Considerable evidence indicates that the lipophilic beta-blocker propranolol is useful in treating organically based aggression. This study looked at the efficacy of a more hydrophilic beta-blocker, nadolol, to treat aggression in chronic psychiatric inpatients.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0160-6689
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
53
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
N
|
|
pubmed:pagination |
41-6
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:1347291-Adult,
pubmed-meshheading:1347291-Aggression,
pubmed-meshheading:1347291-Antipsychotic Agents,
pubmed-meshheading:1347291-Chronic Disease,
pubmed-meshheading:1347291-Double-Blind Method,
pubmed-meshheading:1347291-Drug Therapy, Combination,
pubmed-meshheading:1347291-Female,
pubmed-meshheading:1347291-Hospitalization,
pubmed-meshheading:1347291-Humans,
pubmed-meshheading:1347291-Male,
pubmed-meshheading:1347291-Mental Disorders,
pubmed-meshheading:1347291-Nadolol,
pubmed-meshheading:1347291-Placebos,
pubmed-meshheading:1347291-Psychiatric Status Rating Scales,
pubmed-meshheading:1347291-Severity of Illness Index
|
|
pubmed:year |
1992
|
|
pubmed:articleTitle |
Nadolol to treat aggression and psychiatric symptomatology in chronic psychiatric inpatients: a double-blind, placebo-controlled study.
|
|
pubmed:affiliation |
Department of Psychiatry, Harvard Medical School, Boston, MA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
